Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan; 2nd report QOL survey

INTRODUCTION: Fatty acid oxidation disorders (FAODs) are rare diseases caused by a defective mitochondrial fatty acid oxidation (FAO) enzyme. We recently reported that bezafibrate improved patient quality of life (QOL) based on the SF-36 questionnaire score in patients with FAODs during a 50-week, o...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiraishi, Hideaki, Yamada, Kenji, Oki, Eishin, Ishige, Mika, Fukao, Toshiyuki, Hamada, Yusuke, Sakai, Norio, Ochi, Fumihiro, Watanabe, Asami, Kawakami, Sanae, Kuzume, Kazuyo, Watanabe, Kenji, Sameshima, Koji, Nakamagoe, Kiyotaka, Tamaoka, Akira, Asahina, Naoko, Yokoshiki, Saki, Miyakoshi, Takashi, Oba, Koji, Isoe, Toshiyuki, Hayashi, Hiroshi, Yamaguchi, Seiji, Sato, Norihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661278/
https://www.ncbi.nlm.nih.gov/pubmed/31372341
http://dx.doi.org/10.1016/j.ymgmr.2019.100496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661278/
https://www.ncbi.nlm.nih.gov/pubmed/31372341
http://dx.doi.org/10.1016/j.ymgmr.2019.100496

Ejemplares similares